Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported open-market sales of company common stock. On May 6, 2026, he sold 3,433 shares at $38.00 per share. On May 7, 2026, he sold an additional 1,422 shares at $40.50 per share.
The Form 4 states these transactions were made under an automatic Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged. After these sales, Siegal directly holds 1,118 shares of Vericel common stock, some of which were acquired through the company’s 2015 Employee Stock Purchase Plan.
VCEL (filed by Jonathan D. Siegal) reported a proposed sale of 3,433 shares of Common Stock under Rule 144, with proceeds shown as $130,454.00. The filing lists several prior issuer-side acquisitions (ESPP purchases and restricted stock vesting) with specific lot sizes and dates.
Vericel Corporation reported a Form 144 notice indicating a proposed sale of 5,000 shares of Common Stock. The filing lists Fidelity Brokerage Services LLC and a dollar value of $202,500.00, with the filing date shown as 05/07/2026. The record also shows restricted stock vesting of 1,733 shares on 02/18/2025 and 3,267 shares on 02/22/2025.
Vericel Corporation reported first-quarter 2026 results with total revenue of $68.4 million, up 30% from $52.6 million a year earlier, driven by strong growth in MACI and Epicel. Net loss narrowed to $6.3 million, or $0.12 per share, from $11.2 million.
MACI revenue rose to $56.4 million and Epicel to $10.9 million, while NexoBrid contributed $1.1 million. Vericel ended the quarter with $109.3 million in cash and cash equivalents and $101.3 million in investments, and had no borrowings under its $150 million revolving credit facility.
The company also entered a ten-year agreement with BARDA valued at up to $196.9 million to procure NexoBrid, build vendor-managed inventory, and fund development work, including a potential blast trauma indication and U.S.-based manufacturing capabilities.
Vericel Corporation reported strong growth for the first quarter of 2026, with total revenue up 30% to $68.4 million compared to $52.6 million a year earlier. MACI net revenue rose 22% to $56.4 million and Burn Care revenue grew 91% to $12.0 million, including Epicel revenue growth of 119%.
Gross margin improved to 72%, helping narrow the net loss to $6.3 million, or $0.12 per diluted share, from $11.2 million, or $0.23 per share. Non-GAAP adjusted EBITDA increased 195% to $9.6 million, and free cash flow reached $15.1 million.
The company ended the quarter with approximately $211 million in cash and investments and no debt. Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 to $336 million, with higher targets for both MACI and Burn Care.
VCEL filed a Form 144 notice reporting proposed sale activity for Common shares tied to Fidelity Brokerage Services LLC. The filing shows 3,433 shares with an attributable value of $130,454.00 and identifier 50763319 dated 05/06/2026. The excerpt also lists restricted stock vesting events: 1,383 shares on 02/17/2026, 913 shares on 02/20/2026, and 1,137 shares on 02/22/2026.
Vericel Corp director Kevin F. McLaughlin reported compensation-related equity activity. He exercised 3,200 previously granted Restricted Stock Units (RSUs) into 3,200 shares of common stock, bringing his direct common stock holdings to 18,300 shares after the transactions.
On the same date, he received new awards of 3,200 RSUs and stock options for 8,000 shares of common stock at an exercise price of $33.43 per share. The new RSUs vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026, while the options vest over one year in equal monthly increments, contingent on continued service.
Vericel Corp director Heidi Hagen reported routine equity compensation activity. She exercised 3,200 Restricted Stock Units into 3,200 shares of common stock, bringing her direct common stock holdings to 35,050 shares. She also received a new grant of 3,200 RSUs that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. All transactions reflect awards and exercises rather than open‑market buying or selling.
Vericel Corp director Alan L. Rubino increased his equity-based holdings through routine compensation awards and vesting. He acquired 3,200 shares of common stock via the vesting and conversion of previously granted Restricted Stock Units (RSUs), bringing his direct common stock holdings to 64,194 shares.
He also received a new grant of 3,200 RSUs, each representing a contingent right to one Vericel common share, which vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026. In addition, he was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. These transactions reflect equity compensation and do not include any open-market purchases or sales.
Vericel Corp director Paul K. Wotton reported equity compensation activity rather than open-market trading. He exercised or converted 3,200 shares of Common Stock, bringing his direct holdings to 28,802 shares. The filing shows net share acquisitions only, with no reported sales.
Wotton also received new awards: 3,200 Restricted Stock Units and 8,000 stock options with a conversion or exercise price of $33.43 per share, expiring on April 29, 2036. The options vest over one year in equal monthly increments, while the RSUs vest 100% on the earlier of April 29, 2027 or the first annual stockholders meeting after April 29, 2026. Certain RSUs were deferred into Phantom Stock units under Vericel’s Deferred Compensation Plan and will be settled in shares of Common Stock at Wotton’s elected distribution date.